In This Article:
Indivior (LON:INDV) Full Year 2024 Results
Key Financial Results
-
Revenue: US$1.19b (up 8.7% from FY 2023).
-
Net loss: US$48.0m (down from US$2.00m profit in FY 2023).
-
US$0.36 loss per share (down from US$0.015 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Indivior Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are down 13% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for Indivior (1 doesn't sit too well with us!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.